{"hands_on_practices": [{"introduction": "The decision to use Whole Exome Sequencing (WES) versus a more targeted gene panel is a common and critical choice in both clinical diagnostics and research. This decision is not only driven by the clinical question but also by practical considerations of cost and throughput. This exercise will guide you through the fundamental calculations that underpin the economics of next-generation sequencing, demonstrating how factors like sequencing yield, on-target efficiency, and multiplexing capability directly influence the per-sample cost. By working through this scenario, you will gain a practical appreciation for the trade-offs involved in designing and budgeting for large-scale genomic assays [@problem_id:4396852].", "problem": "A clinical genomics laboratory is planning to run Whole Exome Sequencing (WES) and a targeted Deoxyribonucleic Acid (DNA) panel of $500$ genes on human samples. The laboratory wants to compute the per-sample cost for WES at $100\\times$ mean depth and compare it to the per-sample cost for the $500$-gene panel, accounting for reagent costs, capture kit costs, and instrument amortization. Use the following scientifically grounded assumptions and data, and base your derivation on core definitions of coverage and yield:\n\nFundamental bases:\n- Mean coverage depth is defined as total unique on-target bases divided by the target size, that is, if a run generates $B_{\\text{raw}}$ bases, with on-target fraction $f_{\\text{on}}$ and duplicate fraction $f_{\\text{dup}}$, then the unique on-target bases are $B_{\\text{eff}} = B_{\\text{raw}} \\cdot f_{\\text{on}} \\cdot (1 - f_{\\text{dup}})$, and the mean depth over a target of size $T$ is $D = B_{\\text{eff}} / T$.\n- When pooling $n$ samples (multiplexing) in one run for a fixed $B_{\\text{eff}}$, each sample receives $B_{\\text{eff}}/n$ effective bases; to guarantee a minimum mean depth $D_{\\min}$ over target size $T$, the maximum allowable multiplex is $n = \\left\\lfloor B_{\\text{eff}} / (D_{\\min} \\cdot T) \\right\\rfloor$, where $\\lfloor \\cdot \\rfloor$ is the floor function.\n\nScenario and parameters:\n- Sequencing is performed with paired-end reads of length $L = 150$ bases per read, so each read pair contributes $2L = 300$ bases.\n- WES targets the exome of size $T_{\\text{WES}} = 37 \\times 10^{6}$ bases. Required mean depth is $D_{\\text{WES}} = 100$.\n- The WES run uses a NovaSeq 6000 S1 flow cell generating $R_{\\text{pairs,WES}} = 800 \\times 10^{6}$ read pairs per run. Thus, raw bases per run are $B_{\\text{raw,WES}} = R_{\\text{pairs,WES}} \\cdot 2L$.\n- For WES, the on-target fraction is $f_{\\text{on,WES}} = 0.60$ and the duplicate fraction is $f_{\\text{dup,WES}} = 0.10$.\n- The WES sequencing reagent cost per run is $C_{\\text{seq,WES}} = 3500$ U.S. dollars (USD), and the instrument amortization per run is $C_{\\text{amort,WES}} = 500$ USD.\n- Per-sample WES capture kit cost is $C_{\\text{cap,WES}} = 250$ USD; per-sample library preparation reagents are $C_{\\text{lib}} = 90$ USD; per-sample additional consumables are $C_{\\text{cons}} = 50$ USD.\n\n- The $500$-gene panel has a total targeted exon size $T_{\\text{panel}} = 5 \\times 10^{6}$ bases and requires mean depth $D_{\\text{panel}} = 500$.\n- The panel run uses a NextSeq 2000 P2 flow cell generating $R_{\\text{pairs,panel}} = 400 \\times 10^{6}$ read pairs per run. Thus, raw bases per run are $B_{\\text{raw,panel}} = R_{\\text{pairs,panel}} \\cdot 2L$.\n- For the panel, the on-target fraction is $f_{\\text{on,panel}} = 0.75$ and the duplicate fraction is $f_{\\text{dup,panel}} = 0.05$.\n- The panel sequencing reagent cost per run is $C_{\\text{seq,panel}} = 2400$ USD, and the instrument amortization per run is $C_{\\text{amort,panel}} = 300$ USD.\n- Per-sample panel capture kit cost is $C_{\\text{cap,panel}} = 100$ USD; per-sample library preparation reagents are $C_{\\text{lib}} = 90$ USD; per-sample additional consumables are $C_{\\text{cons}} = 50$ USD.\n\nAssume samples are multiplexed at the maximum integer number that still guarantees the required mean depth for each assay, as defined above. The per-sample sequencing cost is the run-level sequencing reagent cost plus instrument amortization divided by the number of samples multiplexed, added to per-sample capture kit, library, and consumables costs.\n\nCompute the ratio of WES per-sample cost to the panel per-sample cost as a dimensionless decimal number. Round your final ratio to four significant figures.", "solution": "The problem is scientifically grounded, well-posed, objective, and contains all necessary information for a unique solution. The parameters and definitions provided are standard within the field of clinical genomics and bioinformatics. Therefore, the problem is valid, and a full solution can be derived.\n\nThe objective is to compute the ratio of the per-sample cost of Whole Exome Sequencing (WES), $C_{\\text{total,WES}}$, to the per-sample cost of a targeted gene panel, $C_{\\text{total,panel}}$. The total per-sample cost for any assay is the sum of per-sample costs and the distributed run-level costs. The formula for the total per-sample cost, $C_{\\text{total}}$, is:\n$$C_{\\text{total}} = \\frac{C_{\\text{seq}} + C_{\\text{amort}}}{n} + C_{\\text{cap}} + C_{\\text{lib}} + C_{\\text{cons}}$$\nwhere $n$ is the number of samples multiplexed in a single sequencing run. The maximum number of samples, $n$, is determined by the sequencing yield and the required coverage depth, given by:\n$$n = \\left\\lfloor \\frac{B_{\\text{eff}}}{D_{\\min} \\cdot T} \\right\\rfloor$$\nThe effective unique on-target bases, $B_{\\text{eff}}$, are calculated from the raw bases, $B_{\\text{raw}}$, as:\n$$B_{\\text{eff}} = B_{\\text{raw}} \\cdot f_{\\text{on}} \\cdot (1 - f_{\\text{dup}})$$\nThe raw bases, $B_{\\text{raw}}$, depend on the number of read pairs, $R_{\\text{pairs}}$, and the bases per read pair, $2L$:\n$$B_{\\text{raw}} = R_{\\text{pairs}} \\cdot 2L$$\nWe are given the read length $L = 150$ bases, so each read pair contributes $2L = 300$ bases.\n\nFirst, we will calculate the per-sample cost for WES, $C_{\\text{total,WES}}$.\n\nStep 1: Calculate the total raw bases per WES run, $B_{\\text{raw,WES}}$.\n$$B_{\\text{raw,WES}} = R_{\\text{pairs,WES}} \\cdot 2L = (800 \\times 10^{6}) \\cdot (2 \\cdot 150) = 800 \\times 10^{6} \\cdot 300 = 2.4 \\times 10^{11} \\text{ bases}$$\n\nStep 2: Calculate the effective unique on-target bases per WES run, $B_{\\text{eff,WES}}$.\nWith $f_{\\text{on,WES}} = 0.60$ and $f_{\\text{dup,WES}} = 0.10$:\n$$B_{\\text{eff,WES}} = B_{\\text{raw,WES}} \\cdot f_{\\text{on,WES}} \\cdot (1 - f_{\\text{dup,WES}}) = (2.4 \\times 10^{11}) \\cdot 0.60 \\cdot (1 - 0.10) = (2.4 \\times 10^{11}) \\cdot 0.60 \\cdot 0.90 = 1.296 \\times 10^{11} \\text{ bases}$$\n\nStep 3: Calculate the maximum number of multiplexed samples for WES, $n_{\\text{WES}}$.\nWith required depth $D_{\\text{WES}} = 100$ and target size $T_{\\text{WES}} = 37 \\times 10^{6}$ bases:\n$$n_{\\text{WES}} = \\left\\lfloor \\frac{B_{\\text{eff,WES}}}{D_{\\text{WES}} \\cdot T_{\\text{WES}}} \\right\\rfloor = \\left\\lfloor \\frac{1.296 \\times 10^{11}}{100 \\cdot (37 \\times 10^{6})} \\right\\rfloor = \\left\\lfloor \\frac{1.296 \\times 10^{11}}{3.7 \\times 10^{9}} \\right\\rfloor = \\left\\lfloor 35.027... \\right\\rfloor = 35$$\n\nStep 4: Calculate the total per-sample cost for WES, $C_{\\text{total,WES}}$.\nThe run-level costs are $C_{\\text{seq,WES}} = 3500$ and $C_{\\text{amort,WES}} = 500$. The per-sample costs are $C_{\\text{cap,WES}} = 250$, $C_{\\text{lib}} = 90$, and $C_{\\text{cons}} = 50$.\n$$C_{\\text{total,WES}} = \\frac{C_{\\text{seq,WES}} + C_{\\text{amort,WES}}}{n_{\\text{WES}}} + C_{\\text{cap,WES}} + C_{\\text{lib}} + C_{\\text{cons}}$$\n$$C_{\\text{total,WES}} = \\frac{3500 + 500}{35} + 250 + 90 + 50 = \\frac{4000}{35} + 390 \\approx 114.2857 + 390 = 504.2857 \\text{ USD}$$\nTo maintain precision, we use the fractional form: $C_{\\text{total,WES}} = \\frac{4000}{35} + 390 = \\frac{800}{7} + 390 = \\frac{800 + 2730}{7} = \\frac{3530}{7}$.\n\nNext, we will calculate the per-sample cost for the targeted panel, $C_{\\text{total,panel}}$.\n\nStep 1: Calculate the total raw bases per panel run, $B_{\\text{raw,panel}}$.\n$$B_{\\text{raw,panel}} = R_{\\text{pairs,panel}} \\cdot 2L = (400 \\times 10^{6}) \\cdot (2 \\cdot 150) = 400 \\times 10^{6} \\cdot 300 = 1.2 \\times 10^{11} \\text{ bases}$$\n\nStep 2: Calculate the effective unique on-target bases per panel run, $B_{\\text{eff,panel}}$.\nWith $f_{\\text{on,panel}} = 0.75$ and $f_{\\text{dup,panel}} = 0.05$:\n$$B_{\\text{eff,panel}} = B_{\\text{raw,panel}} \\cdot f_{\\text{on,panel}} \\cdot (1 - f_{\\text{dup,panel}}) = (1.2 \\times 10^{11}) \\cdot 0.75 \\cdot (1 - 0.05) = (1.2 \\times 10^{11}) \\cdot 0.75 \\cdot 0.95 = 8.55 \\times 10^{10} \\text{ bases}$$\n\nStep 3: Calculate the maximum number of multiplexed samples for the panel, $n_{\\text{panel}}$.\nWith required depth $D_{\\text{panel}} = 500$ and target size $T_{\\text{panel}} = 5 \\times 10^{6}$ bases:\n$$n_{\\text{panel}} = \\left\\lfloor \\frac{B_{\\text{eff,panel}}}{D_{\\text{panel}} \\cdot T_{\\text{panel}}} \\right\\rfloor = \\left\\lfloor \\frac{8.55 \\times 10^{10}}{500 \\cdot (5 \\times 10^{6})} \\right\\rfloor = \\left\\lfloor \\frac{8.55 \\times 10^{10}}{2.5 \\times 10^{9}} \\right\\rfloor = \\left\\lfloor 34.2 \\right\\rfloor = 34$$\n\nStep 4: Calculate the total per-sample cost for the panel, $C_{\\text{total,panel}}$.\nThe run-level costs are $C_{\\text{seq,panel}} = 2400$ and $C_{\\text{amort,panel}} = 300$. The per-sample costs are $C_{\\text{cap,panel}} = 100$, $C_{\\text{lib}} = 90$, and $C_{\\text{cons}} = 50$.\n$$C_{\\text{total,panel}} = \\frac{C_{\\text{seq,panel}} + C_{\\text{amort,panel}}}{n_{\\text{panel}}} + C_{\\text{cap,panel}} + C_{\\text{lib}} + C_{\\text{cons}}$$\n$$C_{\\text{total,panel}} = \\frac{2400 + 300}{34} + 100 + 90 + 50 = \\frac{2700}{34} + 240 \\approx 79.4118 + 240 = 319.4118 \\text{ USD}$$\nUsing the fractional form: $C_{\\text{total,panel}} = \\frac{2700}{34} + 240 = \\frac{1350}{17} + 240 = \\frac{1350 + 4080}{17} = \\frac{5430}{17}$.\n\nFinally, we compute the ratio of the two costs.\n$$\\text{Ratio} = \\frac{C_{\\text{total,WES}}}{C_{\\text{total,panel}}} = \\frac{3530/7}{5430/17} = \\frac{3530}{7} \\cdot \\frac{17}{5430} = \\frac{353 \\cdot 17}{7 \\cdot 543} = \\frac{6001}{3801}$$\n$$\\text{Ratio} \\approx 1.57879505...$$\nRounding the result to four significant figures gives $1.579$.", "answer": "$$\\boxed{1.579}$$", "id": "4396852"}, {"introduction": "When analyzing WES data from tumor samples, we are observing a composite signal from a heterogeneous mixture of cancerous and normal cells. A key skill in computational oncology is the ability to deconvolve these signals to understand the underlying biology of the tumor. This practice focuses on deriving a foundational model that connects the observed Variant Allele Fraction ($VAF$) to key biological parameters: tumor purity ($p$), local tumor copy number ($C_t$), and normal copy number ($C_n$). This derivation provides a first-principles understanding of how sequencing data quantitatively reflects the architecture of a tumor genome, enabling inferences about a variant's clonality and the sample's composition [@problem_id:4396882].", "problem": "A tumor specimen is profiled by Whole Exome Sequencing (WES). The sequenced DNA is a mixture of tumor-derived molecules and normal stromal molecules. Tumor purity, denoted by $p$, is defined as the fraction of the total sequenced DNA molecules that originate from tumor cells, so that the remaining fraction $1-p$ originates from normal cells. At a genomic locus of interest, the local absolute copy number in tumor cells is $C_{t}$ and the local copy number in normal cells is $C_{n}$. Consider a clonal somatic Single Nucleotide Variant (SNV), defined here as a point mutation present in all tumor cells at this locus and absent from normal cells, and further assume the mutation resides on exactly one of the $C_{t}$ copies within each tumor cell at this locus. Assume that WES reads sample alleles proportionally to their molecular abundance with no allelic bias, that mapping and capture efficiencies are equal between reference and variant alleles at this locus, and that the sequencing depth is sufficiently high for expectations to approximate observed fractions.\n\nUsing only these definitions and assumptions, derive an expression for the expected Variant Allele Fraction (VAF), defined as the fraction of sequencing reads that carry the variant allele at this locus in the tumor sample, as a function of $p$, $C_{t}$, and $C_{n}$. Express your final answer as a single simplified symbolic expression. No numerical evaluation or rounding is required.", "solution": "The problem as stated is scientifically grounded, well-posed, objective, and internally consistent. It provides a simplified but standard model used in computational cancer genomics to relate fundamental quantities. All necessary definitions and assumptions are provided to derive a unique analytical solution. Therefore, the problem is deemed valid.\n\nThe objective is to derive an expression for the expected Variant Allele Fraction (VAF) as a function of tumor purity ($p$), tumor cell copy number ($C_{t}$), and normal cell copy number ($C_{n}$).\n\nThe VAF is defined as the fraction of sequencing reads that carry the variant allele at a specific genomic locus. The problem states that sequencing reads sample alleles proportionally to their molecular abundance. Therefore, the expected VAF is equivalent to the ratio of the number of DNA molecules carrying the variant allele to the total number of DNA molecules at that locus in the sample.\n\nLet $N_{V}$ be the number of molecules (alleles) carrying the single nucleotide variant (SNV), and let $N_{T}$ be the total number of molecules (alleles) at that locus. The VAF is then given by:\n$$\n\\text{VAF} = \\frac{N_{V}}{N_{T}}\n$$\nThe total population of DNA molecules in the sample is a mixture of molecules from tumor cells and normal cells.\n\nFirst, let us establish an expression for the denominator, $N_{T}$. The total number of alleles at the locus is the sum of alleles contributed by the tumor cell population and the normal cell population.\nThe fraction of total DNA originating from tumor cells is $p$. The local copy number in these cells is $C_{t}$. Therefore, the number of alleles contributed by the tumor cell population is proportional to the product $p \\cdot C_{t}$.\nThe fraction of total DNA originating from normal cells is $1-p$. The local copy number in these cells is $C_{n}$. Therefore, the number of alleles contributed by the normal cell population is proportional to the product $(1-p) \\cdot C_{n}$.\n\nLet $K$ be a constant of proportionality that relates the fraction of total DNA to the number of allele molecules at the locus of interest, accounting for factors like the total amount of DNA in the sample. The total number of alleles, $N_{T}$, can be expressed as:\n$$\nN_{T} = K \\cdot (p \\cdot C_{t} + (1-p) \\cdot C_{n})\n$$\n\nNext, we establish an expression for the numerator, $N_{V}$. The problem states that the SNV is somatic and clonal, meaning it is present in all tumor cells but absent from all normal cells. Thus, all variant alleles must originate from the tumor cell population.\nThe problem further specifies that the mutation resides on exactly one of the $C_{t}$ copies within each tumor cell. This means that for the DNA contributed by tumor cells, the fraction of alleles carrying the variant is exactly $\\frac{1}{C_{t}}$.\n\nThe total number of alleles contributed by the tumor population is proportional to $p \\times C_{t}$. To find the number of variant alleles, we multiply this quantity by the fraction of tumor alleles that are variant:\n$$\nN_{V} = K \\cdot (p \\cdot C_{t}) \\cdot \\frac{1}{C_{t}}\n$$\nThe $C_{t}$ terms cancel, simplifying the expression for the number of variant alleles:\n$$\nN_{V} = K \\cdot p\n$$\n\nFinally, we can substitute the expressions for $N_{V}$ and $N_{T}$ into the definition of VAF:\n$$\n\\text{VAF} = \\frac{N_{V}}{N_{T}} = \\frac{K \\cdot p}{K \\cdot (p \\cdot C_{t} + (1-p) \\cdot C_{n})}\n$$\nThe proportionality constant $K$ cancels from the numerator and the denominator, yielding the final expression for the expected VAF:\n$$\n\\text{VAF} = \\frac{p}{p C_{t} + (1-p) C_{n}}\n$$\nThis expression relates the expected Variant Allele Fraction to the tumor purity, the tumor-specific copy number, and the normal-specific copy number, based solely on the definitions and assumptions provided in the problem statement.", "answer": "$$\n\\boxed{\\frac{p}{p C_{t} + (1-p) C_{n}}}\n$$", "id": "4396882"}, {"introduction": "The final step in the diagnostic WES workflow is the interpretation and classification of identified variants, a process governed by the ACMG/AMP guidelines. However, it is common to encounter variants with conflicting lines of evidence, where some data support pathogenicity while other data suggest a benign impact. This exercise demonstrates how to resolve such conflicts using a rigorous quantitative framework based on Bayes' theorem. By converting qualitative evidence codes into calibrated Likelihood Ratios ($LR$), you will learn to formally combine multiple pieces of evidence to calculate a final posterior probability of pathogenicity, a core competency for any genomic diagnostician [@problem_id:4396807].", "problem": "A clinician orders Whole Exome Sequencing (WES) for a proband with a phenotype highly consistent with a known haploinsufficiency disorder caused by loss-of-function variants in a specific gene. WES identifies a rare intronic variant at position $-2$ relative to the canonical acceptor site of an exon in this gene. Variant interpretation under the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) framework yields conflicting lines of evidence that must be combined quantitatively. Assume the following scientifically calibrated Likelihood Ratios (LRs) for evidence strength are applicable and that, conditional on the true pathogenicity state, these evidence items can be treated as approximately independent:\n- Predicted loss of function via splicing consistent with disease mechanism (PVS1 at moderate strength): LR $= 4.33$.\n- Well-controlled functional minigene assay showing predominantly aberrant splicing with reduced normal transcript (PS3 at moderate strength): LR $= 4.33$.\n- Multiple independent in silico splicing predictors concordantly support a deleterious splice effect (PP3 at supporting strength): LR $= 2.08$.\n- Allele frequency modestly exceeds the threshold expected for a fully penetrant disorder with the observed prevalence and genetic architecture (BS1 at moderate strength): LR $= 0.23$.\n- An alternative molecular diagnosis explaining the proband’s phenotype is identified elsewhere in the exome (BP5 at supporting strength): LR $= 0.48$.\n\nAssume a prior probability of pathogenicity for such a rare splice-region variant in this gene, given the clinical context, of $0.10$.\n\nStarting from Bayes’ theorem and the definition of Likelihood Ratios under conditional independence, derive an expression for the posterior probability of pathogenicity given the combined evidence, and then compute its numerical value. Round your final numerical answer to four significant figures. Express the final result as a unitless decimal fraction between $0$ and $1$.", "solution": "The problem is subjected to validation by first extracting the given information.\n\nGivens:\n1.  A rare intronic variant is identified at position $-2$ relative to a canonical acceptor site.\n2.  The problem concerns combining evidence under the ACMG/AMP framework.\n3.  The evidence items are treated as conditionally independent given the true pathogenicity state.\n4.  Likelihood Ratio for PVS1 (moderate): $LR_{PVS1} = 4.33$.\n5.  Likelihood Ratio for PS3 (moderate): $LR_{PS3} = 4.33$.\n6.  Likelihood Ratio for PP3 (supporting): $LR_{PP3} = 2.08$.\n7.  Likelihood Ratio for BS1 (moderate): $LR_{BS1} = 0.23$.\n8.  Likelihood Ratio for BP5 (supporting): $LR_{BP5} = 0.48$.\n9.  Prior probability of pathogenicity for the variant: $P(\\text{Pathogenic}) = 0.10$.\n\nValidation Results:\nThe problem is scientifically grounded, situated within the established quantitative framework for genetic variant interpretation. The use of Bayes' theorem, likelihood ratios, and the assumption of conditional independence for combining ACMG/AMP evidence codes is a standard and well-documented methodology in molecular pathology and medical genetics. The provided Likelihood Ratio values are consistent with calibrated strengths found in scientific literature. The problem is well-posed, objective, self-contained, and presents a realistic scenario without internal contradictions or ambiguities. Therefore, the problem is deemed valid.\n\nThe solution proceeds by applying Bayes' theorem to update the prior probability of pathogenicity in light of the new evidence. It is most convenient to work with the odds form of Bayes' theorem, especially when dealing with likelihood ratios.\n\nLet $Path$ be the event that the variant is pathogenic, and $NP$ be the event that the variant is not pathogenic (benign). Let $E$ be the combined evidence from the five specified ACMG/AMP criteria. The objective is to compute the posterior probability of pathogenicity, $P(Path | E)$.\n\nThe prior probability of pathogenicity is given as $P(Path) = 0.10$.\nThe prior probability of the variant not being pathogenic is therefore $P(NP) = 1 - P(Path) = 1 - 0.10 = 0.90$.\n\nThe prior odds of pathogenicity are defined as the ratio of the prior probabilities:\n$$\n\\text{Odds}(Path) = \\frac{P(Path)}{P(NP)} = \\frac{0.10}{0.90} = \\frac{1}{9}\n$$\n\nThe posterior odds of pathogenicity given the evidence $E$ are related to the prior odds by the combined likelihood ratio, $LR_{comb}$:\n$$\n\\text{Odds}(Path | E) = \\text{Odds}(Path) \\times LR_{comb}\n$$\n\nThe likelihood ratio for a single piece of evidence $E_i$ is defined as $LR_i = \\frac{P(E_i | Path)}{P(E_i | NP)}$. The problem states that the individual pieces of evidence are conditionally independent. This means that the probability of observing the combined evidence given the pathogenicity state is the product of the probabilities of observing each piece of evidence:\n$$\nP(E | Path) = P(E_1, E_2, E_3, E_4, E_5 | Path) = \\prod_{i=1}^{5} P(E_i | Path)\n$$\nAnd similarly for the non-pathogenic state:\n$$\nP(E | NP) = \\prod_{i=1}^{5} P(E_i | NP)\n$$\n\nTherefore, the combined likelihood ratio, $LR_{comb}$, is the product of the individual likelihood ratios:\n$$\nLR_{comb} = \\frac{P(E | Path)}{P(E | NP)} = \\frac{\\prod_{i=1}^{5} P(E_i | Path)}{\\prod_{i=1}^{5} P(E_i | NP)} = \\prod_{i=1}^{5} \\frac{P(E_i | Path)}{P(E_i | NP)} = \\prod_{i=1}^{5} LR_i\n$$\n\nThe specified likelihood ratios are:\n$LR_1 = LR_{PVS1} = 4.33$ (Pathogenic, Moderate)\n$LR_2 = LR_{PS3} = 4.33$ (Pathogenic, Moderate)\n$LR_3 = LR_{PP3} = 2.08$ (Pathogenic, Supporting)\n$LR_4 = LR_{BS1} = 0.23$ (Benign, Moderate)\n$LR_5 = LR_{BP5} = 0.48$ (Benign, Supporting)\n\nNote that likelihood ratios greater than $1$ favor pathogenicity, while those less than $1$ favor a benign status. The combined likelihood ratio is calculated as:\n$$\nLR_{comb} = LR_{PVS1} \\times LR_{PS3} \\times LR_{PP3} \\times LR_{BS1} \\times LR_{BP5}\n$$\n$$\nLR_{comb} = (4.33) \\times (4.33) \\times (2.08) \\times (0.23) \\times (0.48)\n$$\n$$\nLR_{comb} = (4.33)^{2} \\times 2.08 \\times 0.23 \\times 0.48\n$$\n$$\nLR_{comb} = 18.7489 \\times 2.08 \\times 0.23 \\times 0.48\n$$\n$$\nLR_{comb} \\approx 4.3053474\n$$\n\nNow, we can calculate the posterior odds of pathogenicity:\n$$\n\\text{Odds}(Path | E) = \\text{Odds}(Path) \\times LR_{comb} = \\frac{1}{9} \\times 4.3053474 \\approx 0.4783719\n$$\n\nFinally, we convert the posterior odds back to a posterior probability. The relationship between probability $P(A)$ and odds $\\text{Odds}(A)$ is given by:\n$$\nP(A) = \\frac{\\text{Odds}(A)}{1 + \\text{Odds}(A)}\n$$\nApplying this to our posterior odds:\n$$\nP(Path | E) = \\frac{\\text{Odds}(Path | E)}{1 + \\text{Odds}(Path | E)}\n$$\n$$\nP(Path | E) = \\frac{0.4783719}{1 + 0.4783719} = \\frac{0.4783719}{1.4783719}\n$$\n$$\nP(Path | E) \\approx 0.3235835\n$$\n\nThe problem requires the final answer to be rounded to four significant figures.\n$$\nP(Path | E) \\approx 0.3236\n$$\nThis result indicates that despite some strong evidence for pathogenicity (PVS1, PS3), the conflicting evidence (especially the high allele frequency in BS1 and an alternative diagnosis in BP5) has substantially reduced the probability of this variant being pathogenic from an initial prior of $0.10$, but has ultimately increased it. The final posterior probability is approximately $0.3236$. The initial understanding might be that conflicting evidence would lower the probability, but the product of LRs greater than $1$ was larger than the product of LRs less than $1$, so the combined LR is greater than $1$, increasing the odds. Let's re-evaluate the calculation: $LR_{pathogenic} = 4.33 \\times 4.33 \\times 2.08 \\approx 38.998$. $LR_{benign} = 0.23 \\times 0.48 = 0.1104$. $LR_{comb} = 38.998 \\times 0.1104 \\approx 4.305$. This is correct. The combined evidence is indeed pathogenic, increasing the posterior probability relative to the prior.", "answer": "$$\\boxed{0.3236}$$", "id": "4396807"}]}